A Device and Method to Remove Excess Glucose in the Small intestine for Prevention and Treatment of Type 2 Diabetes and Obesity
Background: Type 2 Diabetes, also known as non-insulin dependent diabetes mellitus (NIDDM) or adult-onset diabetes is the most common form of diabetes affecting 90-95% of the 21 million Americans diagnosed with the disease. While traditionally diagnosed in adults over the age of 40, it is increasingly seen in children and adolescents, an increase thought to be linked to the rising rates of obesity in this age group. Unlike those with Type 1 Diabetes, people with Type 2 diabetes produce insulin - however, the amount of insulin their body produces is insufficient or their body is unable to recognize the insulin to use it properly (insulin resistance). In either situation, glucose can build in the bloodstream and over time can lead to a host of other conditions from heart disease, stroke and nerve damage.
Treatment of Type 2 diabetes initially involves the adjustment of diet, exercise and weight loss in obese patients to control glucose and blood pressure. When diet and exercise are insufficient, anti-diabetic drugs are used to control blood glucose and consist of several different classes that either stimulate the production of insulin or increasing cellular uptake of insulin. If anti-diabetic drugs fail to properly control blood glucose, insulin therapy may be required. Technology: Researchers at the University of California Irvine are developing a swallow-able device that blocks the absorption of glucose that would elicit an unhealthy rise of insulin in the blood stream. The device is capsule-sized and intended to be swallowed before or at mealtime. Application: The present invention is an alternative treatment for anti-diabetic agents or insulin for individuals with Type 2 diabetes.
Type of Offer:
« More Biomedical Patents